Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genentech, Inc.
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
- Large Molecule
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.